MedPath

Suvorexant

Generic Name
Suvorexant
Brand Names
Belsomra
Drug Type
Small Molecule
Chemical Formula
C23H23ClN6O2
CAS Number
1030377-33-3
Unique Ingredient Identifier
081L192FO9
Background

Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

Indication

Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Associated Conditions
Insomnia
Clinical Trials
Related News

A Pilot Study of Suvorexant for Insomnia in Parkinson Disease

Phase 4
Completed
Conditions
Insomnia
Interventions
Drug: Placebo
First Posted Date
2016-04-06
Last Posted Date
2024-08-20
Lead Sponsor
Burdick, Daniel, M.D.
Target Recruit Count
21
Registration Number
NCT02729714
Locations
🇺🇸

Evergreenhealth Booth Gardner Parkinsons Care Center, Kirkland, Washington, United States

Suvorexant and Trauma Related Insomnia

Phase 4
Completed
Conditions
Insomnia
Posttraumatic Stress Disorder
Interventions
Other: placebo
First Posted Date
2016-03-10
Last Posted Date
2023-02-15
Lead Sponsor
Howard University
Target Recruit Count
41
Registration Number
NCT02704754
Locations
🇺🇸

Clinical Research Unit; Howard University Hospital, Washington, District of Columbia, United States

Suvorexant in Insomnia Co-morbid With Fibromyalgia

Phase 4
Terminated
Conditions
Insomnia
Fibromyalgia
Interventions
Drug: placebo
First Posted Date
2016-02-17
Last Posted Date
2021-06-16
Lead Sponsor
Henry Ford Health System
Target Recruit Count
10
Registration Number
NCT02684136
Locations
🇺🇸

HFHS Sleep Disorders Ctr, Detroit, Michigan, United States

A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia

Phase 4
Conditions
Depression
Major Depressive Disorder
Insomnia
MDD
Interventions
Drug: Placebo
First Posted Date
2016-01-29
Last Posted Date
2019-02-27
Lead Sponsor
Institute for Advanced Medical Research, Alpharetta, GA
Target Recruit Count
74
Registration Number
NCT02669030
Locations
🇺🇸

Medical College of GA at Augusta Univeristy, Augusta, Georgia, United States

🇺🇸

Institute for Advanced Medical Research @ Mercer Univeristy, Atlanta, Georgia, United States

The Role of Orexin in Human Panic Disorder

Phase 4
Completed
Conditions
Panic Disorder
Interventions
Drug: placebo
First Posted Date
2015-11-01
Last Posted Date
2021-07-02
Lead Sponsor
University of California, San Francisco
Target Recruit Count
3
Registration Number
NCT02593682
Locations
🇺🇸

UCSF Fresno Medical Education Program, Fresno, California, United States

Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder

Phase 4
Completed
Conditions
Bipolar Disorder
Insomnia
Interventions
Drug: Placebo
First Posted Date
2015-08-19
Last Posted Date
2022-10-06
Lead Sponsor
Stanford University
Target Recruit Count
61
Registration Number
NCT02527564
Locations
🇺🇸

Stanford University, Stanford, California, United States

Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers

Phase 4
Completed
Conditions
Sleep Disorder, Shift-Work
Interventions
Drug: Placebo
First Posted Date
2015-07-08
Last Posted Date
2020-07-01
Lead Sponsor
VA Palo Alto Health Care System
Target Recruit Count
19
Registration Number
NCT02491788
Locations
🇺🇸

VA Palo Alto Health Care System, Palo Alto, California, United States

Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)

Phase 1
Completed
Conditions
Sleep Apnea
Interventions
Drug: Matching Placebo
First Posted Date
2011-02-21
Last Posted Date
2018-09-21
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
26
Registration Number
NCT01300455

Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)

Phase 1
Completed
Conditions
Insomnia
Interventions
Drug: Placebo
First Posted Date
2011-02-10
Last Posted Date
2018-09-21
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
25
Registration Number
NCT01293006

Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)

Phase 3
Completed
Conditions
Primary Insomnia
Interventions
First Posted Date
2010-04-01
Last Posted Date
2019-08-28
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1020
Registration Number
NCT01097629
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy